Spectrum Pharma (SPPI) Misses Q4 EPS by 7c

Spectrum Pharma (NASDAQ: SPPI) reported Q4 EPS of ($0.36), $0.07 worse than the analyst estimate of ($0.29).

“The Fast Track designation for poziotinib is a significant achievement towards an expedited review,” said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. “In addition, we are delighted that the FDA has scheduled the pre-approval inspection at the ROLONTIS manufacturing facility for May 2021. The company has made tremendous progress advancing our development programs and conducting our clinical trials, despite the challenges of the global pandemic. I am proud of our employees who demonstrated resiliency and creativity during these unprecedented times.”

For earnings history and earnings-related data on Spectrum Pharma (SPPI) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Femasys Inc. (FEMY) Misses Q2 EPS by 20c
• Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c